Safety and Efficacy Assessments of Osalmid in Multiple Myeloma

• Status: Active, not recruiting
• Trial end date: 2021-05-18
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the safety and efficacy of a traditional cholagogue drug osalmid, 2-hydroxy-N-(4-hydroxyphenyl)-benzamide, in the treatment of multiple myeloma (MM).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai 10th People's Hospital
• Collaborator: Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Criteria

Inclusion Criteria:

1. Patients with age≥ 18 years old who are willing to receive the treatment of osalmid;

2. Patients must be diagnosed with active and measurable (symptomatic) multiple myeloma according to IMWG 2003/WHO 2008(V4) MM diagnosis criteria detailed as following:1). Positive M protein in serum and/or urine; 2). Pathologically diagnosed with multiple myeloma or found colonic plasma cells in bone marrow; 3). At least one symptom of related organ damage or tissue lesion: a. hypercalcemia: serum calcium increases 0.25mmol/L or more over upper limit of normal value(ULN) or > 2.75mmol/L; b. anemia: Hemoglobin decreases 20g/L or more over lower limit of normal value(LLN) or <100g/L；c. bone lesion: lytic bone lesion or osteoporosis accompanied with compressive fracture (confirmed with MRI、CT or PET-CT); d. others: symptomatic hyperviscosity, amyloidosis, recurrent infection (more than twice within 12 months);

3. Eastern Cancer Organization Group (ECOG) score≤2 and expected survival>2 months;

4. Belongs to "measurable disease": serum M protein ≥10g/L and/or 24 hour urine M protein ≥200mg;

5. No active infectious diseases;

6. No severe organic dysfunction (except renal function insufficiency caused by multiple myeloma), lab results must meet the following criteria (within 7 days before initiation of therapy): a. Total bilirubin ≤ 1.5*ULN (same age group); b. AST and ALT ≤ 2.5*ULN (same age group); c. Cardiac enzyme < 2*ULN (same age group); d. Normal ejection fraction confirmed in echo;

7. Able to swallow oral medicine;

8. Volunteer to participate into this clinical trial and the informed consents must be written by patients themselves or their direct relatives. Authorized medical attorney or direct relatives can write the informed consents if it is not good for patients' treatment when consider the severity of their disease.

Exclusion Criteria:

1. Received anti-myeloma treatment before (not include radiotherapy, bisphosphonates or single short term steroids treatment [the dose and duration of prednisone should be no more than 40mg/d and 4 days and should discontinue this treatment within 14 days before the enrollment]);

2. Primary or secondary plasma cell leukemia;

3. Positive HIV tests or active infection phase of HAV, HBV and HCV; or HBV DNA copies >104/ml；AST and ALT > 2.5*ULN (same age group);

4. Severe diseases that threaten patients with unacceptable risks; these diseases include but are not confined to unstable heart diseases, which can be defined as cardiac accidents such as MI within 6 months, NYHA stage Ⅲ-Ⅳ heart failure, uncontrolled atrial fibrillation or hypertension and myeloma requiring long term administration of steroids or immune-inhibitors;

5. Renal failure requiring hemodialysis or peritoneal dialysis;

6. Severe embolic or thrombotic events before therapy;

7. Major surgery within 30 days before being enrolled;

8. Total obstruction of biliary tract;

9. Glaucoma;

10. History of malignancies except multiple myeloma unless being cured for more than 3 years;

11. Severe allergic to osalmide capsule;

12. Gestation, lactation or disagreed pregnancy;

13. Severe infectious diseases (uncured tuberculosis, pulmonary aspergillosis);

14. Seizures requiring medicines, patients with dementias and other mental disorders who cannot understand or obey the protocol;

15. Substance abuse, medical, psychological, or social conditions that may interfere with the subject's compliance in the study or assessment of the results of the study;

16. Severe liver and kidney dysfunction;

17. Patients who are considered unsuitable for enrollment by investigators.